STOCK TITAN

Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS) announced it will release its financial results and key pipeline updates for Q1 2022 on May 9, 2022, after U.S. markets close. The company focuses on developing innovative cancer treatments and has advanced six investigational medicines into clinical trials. These include combination therapies targeting TIGIT, PD-1, and the adenosine axis, among others. Founded in 2015, Arcus aims to expedite the development of medicines to improve cancer patient outcomes globally.

Positive
  • Advancing six investigational medicines into clinical studies.
  • Focus on developing differentiated cancer therapies.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March 31, 2022 after the U.S. markets close on Monday, May 9, 2022.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Investor Inquiries

Pia Banerjee

Head of Investor Relations & Strategy

(617) 459-2006

pbanerjee@arcusbio.com

Source: Arcus Biosciences

FAQ

When will Arcus Biosciences report its Q1 2022 financial results?

Arcus Biosciences will report its Q1 2022 financial results on May 9, 2022, after U.S. market close.

What is the primary focus of Arcus Biosciences?

Arcus Biosciences focuses on developing differentiated molecules and combination therapies for cancer.

How many investigational medicines has Arcus advanced to clinical studies?

Arcus has advanced six investigational medicines into clinical studies.

What cancer targets are being studied by Arcus Biosciences?

Arcus is studying combinations targeting TIGIT, PD-1, and the adenosine axis.

Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD